Pipeline: Next Gen IO Products

Using our broadly versatile SnAP technology both of our programs combine clinically validated pieces in a unique way to create a ‘whole greater than the sum of its parts’ … for truly targeted delivery of immune system function and, hence, tumor killing.  As a result, we feel our two IO programs are technically derisked, yet still differentiated.
MDT101 "MeKine"

The proven power of cytokines combined with high tumor specificity of antibodies:

  • "Masked"/deactivated cytokine (IL-2)

  • Fused to antibody via protease cleavable linkers

​​

Resulting in:
  • Potent and specific tumor cell killing

  • Improved therapeutic window

MDT201 "MeCAR"

A single T-cell construct (allogenic or autologous) for use against multiple tumor types.  Tumor-targeting antibody dosed separately for unparalleled control: 

  • T-cell fused to meditope peptide

  • Tumor-targeting antibody/antibodies dosed separately

​​

Resulting in:

  • Unparalleled specificity and control of T-cell activation and potency

  • Reduced development time and manufacturing cost

© Meditope Biosciences